Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis

Journal of Infectious Diseases

Volumn 207, Issue 7, 2013, Pages 1066-1074

  Ben Ami, Ronen ^a,b   Albert, Nathaniel D ^b   Lewis, Russell E ^b   Kontoyiannis, Dimitrios P ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

angiogenesis inducing agents; animal model; fibroblast growth factor 2; invasive pulmonary aspergillosis; vascular endothelial growth factor A

Indexed keywords

AMPHOTERICIN B; FIBROBLAST GROWTH FACTOR 2; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; SODIUM CHLORIDE; VASCULOTROPIN 165;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FUNGAL VIRULENCE; FUNGUS GROWTH; INVASIVE ASPERGILLOSIS; LUNG PARENCHYMA; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SURVIVAL RATE;

AMPHOTERICIN B; ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NEOVASCULARIZATION, PHYSIOLOGIC; NEUTROPHILS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874740459     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis940     Document Type: Article

References (33)

1. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-100.
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15. (Pubitemid 34851833)
3. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289-97. (Pubitemid 46717290)
4. Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol 2010; 150:406-17.
5. Ben-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 2009; 114:5393-9.
6. Paterson PJ, Seaton S, Prentice HG, Kibbler CC. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 2003; 52:873-6. (Pubitemid 37407821)
7. Rankin NE. Disseminated aspergillosis and moniliasis associated with agranulocytosis and antibiotic therapy. Br Med J 1953; 1:918-9.
8. Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73:494-503. (Pubitemid 40041144)
9. Stergiopoulou T, Meletiadis J, Roilides E, et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 2007; 127:349-55. (Pubitemid 46806327)
10. Grahl N, Puttikamonkul S, Macdonald JM, et al. In vivo hypoxia and a fungal alcohol dehydrogenase influence the pathogenesis of invasive pulmonary aspergillosis. PLoS Pathog 2011; 7:e1002145.
11. Willger SD, Puttikamonkul S, Kim KH, et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog 2008; 4:e1000200.
12. Ben-Ami R, Kontoyiannis DP. A nonlethal murine cutaneous model of invasive aspergillosis. Methods Mol Biol 2012; 845:569-82.
13. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard M38-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2008.
14. Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/ reperfusion injury. Proc Natl Acad Sci U S A 2006; 103:19866-71. (Pubitemid 46037522)
15. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293:293-7. (Pubitemid 32694744)
16. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45:3474-81. (Pubitemid 33107865)
17. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190:1464-71. (Pubitemid 39332186)
18. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60. (Pubitemid 351265310)
19. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5:e219.
20. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68. (Pubitemid 43271379)
21. Kradin RL, Mark EJ. The pathology of pulmonary disorders due to Aspergillus spp. Arch Pathol Lab Med 2008; 132:606-14. (Pubitemid 351489614)
22. Sau K, Mambula SS, Latz E, Henneke P, Golenbock DT, Levitz SM. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003; 278:37561-8. (Pubitemid 37175278)
23. Roilides E, Lyman CA, Filioti J, et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46:1974-6. (Pubitemid 34535224)
24. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237:97-132. (Pubitemid 28554861)
25. Nagy JA, Feng D, Vasile E, et al. Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab Invest 2006; 86:767-80. (Pubitemid 44100476)
26. Lopes Bezerra LM, Filler SG. Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity. Blood 2004; 103:2143-9. (Pubitemid 38326231)
27. Kamai Y, Chiang LY, Lopes Bezerra LM, et al. Interactions of Aspergillus fumigatus with vascular endothelial cells. Med Mycol 2006; 44 (Suppl 1):S115-7.
28. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81:1-5. (Pubitemid 46028489)
29. Maulik N. Redox signaling of angiogenesis. Antioxid Redox Signal 2002; 4:805-15. (Pubitemid 35246944)
30. Millner PD, Marsh PB, Snowden RB, Parr JF. Occurrence of Aspergillus fumigatus during composting of sewage sludge. Appl Environ Microbiol 1977; 34:765-72. (Pubitemid 8244942)
31. Rhodes JC. Aspergillus fumigatus: growth and virulence. Med Mycol 2006; 44(Suppl 1):S77-81.
32. Cooney NM, Klein BS. Fungal adaptation to the mammalian host: it is a new world, after all. Curr Opin Microbiol 2008; 11:511-6.
33. Trujillo A, McGee C, Cogle CR. Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol 2012; 2012:128608.